[The new scheme of cavinton application to the treatment of chronic neurosensory loss of hearing].
The objective of this study was to evaluate results of the new therapeutic modality for the management of chronic neurosensory loss of hearing based on the use of caviton. The open randomized study involved 50 patients. Criteria for the efficiency of therapy included the patients' complaints, self-evaluation of tympanophonia based on the visual-analogous scale, results of audiologic examination and Doppler ultrasound of carotid and vertebral arteries. Significant improvement of audiologic characteristics was documented in 80% of the patients; ultrasound examination showed that most of them tended to benefit from caviton therapy and reported reduction of tympanophonia. It is concluded that the new caviton dosing scheme for the treatment of neurosecretory loss of hearing is well tolerated by the patients and can be recommended for more extensive clinical application.
Afon'kin
V Iu
VIu
Dobretsov
K G
KG
Sipkin
A V
AV
D000158:Acoustic Impedance Tests; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002121:Calcium Channel Blockers; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D006309:Hearing / Q000187:drug effects / Q000502:physiology; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D018697:Nootropic Agents / Q000008:administration & dosage*; D016896:Treatment Outcome; D014748:Vinca Alkaloids / Q000008:administration & dosage*
D002121:Calcium Channel Blockers; D018697:Nootropic Agents; D014748:Vinca Alkaloids; C013983:vinpocetine